17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism.
17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. In preparation for clinical studies, nuclear hormone receptor and P450 interactions for HE3235 and major metabolites were characterized in vitro, and pharmacokinetics and metabolite profiles were studied in rodents, dogs, and monkeys. Four-week safety studies conducted in rats and dogs indicated a substantial margin of safety for clinical use, and no evidence of electrocardiographic or neurological effects, although anorexia, thrombocytopenia, and hypokalemia were identified as potentially dose-limiting toxicities at superpharmacological exposures. Pharmacokinetics and drug metabolism have been studied in prostate cancer patients.
Ahlem
Clarence
C
Harbor BioSciences, Inc., 9171 Towne Centre Drive, Suite 181, San Diego, CA 92122, USA. cahlem@harborbiosciences.com
Kennedy
Michael
M
Page
Theodore
T
Bell
David
D
Delorme
Evelyn
E
Villegas
Sonia
S
Reading
Chris
C
White
Steven
S
Stickney
Dwight
D
Frincke
James
J
D000284:Administration, Oral; D000732:Androstanols / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D000735:Androstenedione / Q000097:blood; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D001711:Biotransformation; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000378:metabolism*; D003687:Dehydroepiandrosterone / Q000097:blood; D004285:Dogs; D004334:Drug Administration Schedule; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D055432:Metabolomics; D051379:Mice; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D013045:Species Specificity; D053719:Tandem Mass Spectrometry; D013739:Testosterone / Q000097:blood; D015533:Transcriptional Activation / Q000187:drug effects; D014162:Transfection
C540077:17-ethynylandrostane-3,17-diol; D000732:Androstanols; D018931:Antineoplastic Agents, Hormonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D003577:Cytochrome P-450 Enzyme System
J Immunol. 2006 Jun 15;176(12):7371-8
16751381
Mutat Res. 1975 Feb;31(1):9-15
48190
J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):57-63
19167490
Toxicol Appl Pharmacol. 1977 Jun;40(3):589-91
882989
J Pharmacol Exp Ther. 2003 Oct;307(1):306-13
12893835
Fundam Appl Toxicol. 1988 Aug;11(2):189-206
3146518
Mutat Res. 1975 Dec;31(6):347-64
768755
Mutat Res. 1973 May;18(2):187-90
4351282
Endocrinology. 2006 Dec;147(12):5806-16
16959841
Neoplasia. 2009 Nov;11(11):1216-25
19881957
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13589-94
12370428
J Pharmacol Exp Ther. 2010 Apr;333(1):70-80
20068030
Br J Cancer. 2009 Apr 7;100(7):1068-72
19337256
Horm Metab Res. 1992 Oct;24(10):488-91
1464416
Arch Biochem Biophys. 1997 Oct 1;346(1):161-9
9328296
Eur J Pharmacol. 1974 Jun;27(1):1-4
4853341
Biochem J. 2000 Oct 1;351(Pt 1):67-77
10998348
Mutat Res. 1976 Feb;38(1):3-32
768757
Mutat Res. 1994 Jun;312(3):293-304
7514741
J Clin Endocrinol Metab. 2004 Jun;89(6):2928-35
15181079
Environ Mutagen. 1985;7(1):1-51
3967632
J Clin Oncol. 2003 Apr 1;21(7):1232-7
12663709
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Neurobehav Toxicol. 1979 Fall;1(3):233-6
551317
Mutat Res. 1983 May;113(3-4):173-215
6341825